NEULAND LABORATORIES
Quarterly Results Analysis [Dec2023]
NEULAND LABORATORIES Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 Audited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹393 Cr | ₹418 Cr | ₹363 Cr | ₹407 Cr | ₹269 Cr | ₹294 Cr | ₹221 Cr | ₹256 Cr |
Expenses | ₹272 Cr | ₹280 Cr | ₹266 Cr | ₹287 Cr | ₹215 Cr | ₹224 Cr | ₹193 Cr | ₹217 Cr |
Operating Income | ₹121 Cr | ₹137 Cr | ₹97 Cr | ₹120 Cr | ₹54 Cr | ₹69 Cr | ₹29 Cr | ₹39 Cr |
Other Income | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹8 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr |
Interest | ₹4 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
Depreciation | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹12 Cr |
Profit Before Tax | ₹104 Cr | ₹122 Cr | ₹83 Cr | ₹110 Cr | ₹39 Cr | ₹53 Cr | ₹13 Cr | ₹24 Cr |
Profit After Tax | ₹81 Cr | ₹89 Cr | ₹62 Cr | ₹85 Cr | ₹31 Cr | ₹38 Cr | ₹10 Cr | ₹22 Cr |
EPS | ₹63.09 | ₹69.18 | ₹47.96 | ₹65.53 | ₹23.68 | ₹29.81 | ₹7.73 | ₹16.88 |
Industry Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | 5.7% | -7.9% | 288.4% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
NEULAND LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -5.97 % |
Y-o-Y | 45.90 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹393 Cr | -5.97 | |
Sep2023 | ₹418 Cr | 15.08 | |
Jun2023 | ₹363 Cr | -10.83 | |
Mar2023 | ₹407 Cr | 51.19 | |
Dec2022 | ₹269 Cr | -8.33 | |
Sep2022 | ₹294 Cr | 32.80 | |
Jun2022 | ₹221 Cr | -13.56 | |
Mar2022 | ₹256 Cr | - |
NEULAND LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -11.80 % |
Y-o-Y | 124.22 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹121 Cr | -11.80 | |
Sep2023 | ₹137 Cr | 41.86 | |
Jun2023 | ₹97 Cr | -19.14 | |
Mar2023 | ₹120 Cr | 121.62 | |
Dec2022 | ₹54 Cr | -21.96 | |
Sep2022 | ₹69 Cr | 142.27 | |
Jun2022 | ₹29 Cr | -26.41 | |
Mar2022 | ₹39 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -6.20 % |
Y-o-Y | 53.66 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 30.87% | -6.20 | |
Sep2023 | 32.91% | 23.26 | |
Jun2023 | 26.7% | -9.31 | |
Mar2023 | 29.44% | 46.54 | |
Dec2022 | 20.09% | -14.84 | |
Sep2022 | 23.59% | 82.44 | |
Jun2022 | 12.93% | -14.88 | |
Mar2022 | 15.19% | - |
NEULAND LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -8.80 % |
Y-o-Y | 166.43 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹81 Cr | -8.80 | |
Sep2023 | ₹89 Cr | 44.23 | |
Jun2023 | ₹62 Cr | -26.81 | |
Mar2023 | ₹85 Cr | 176.76 | |
Dec2022 | ₹31 Cr | -20.58 | |
Sep2022 | ₹38 Cr | 285.93 | |
Jun2022 | ₹10 Cr | -54.24 | |
Mar2022 | ₹22 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -3.00 % |
Y-o-Y | 82.56 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 20.72 % | -3.00 | |
Sep2023 | 21.36 % | 25.28 | |
Jun2023 | 17.05 % | -17.91 | |
Mar2023 | 20.77 % | 83.00 | |
Dec2022 | 11.35 % | -13.36 | |
Sep2022 | 13.1 % | 190.47 | |
Jun2022 | 4.51 % | -47.00 | |
Mar2022 | 8.51 % | - |
NEULAND LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -8.80 % |
Y-o-Y | 166.43 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹63.09 | -8.80 | |
Sep2023 | ₹69.18 | 44.25 | |
Jun2023 | ₹47.96 | -26.81 | |
Mar2023 | ₹65.53 | 176.73 | |
Dec2022 | ₹23.68 | -20.56 | |
Sep2022 | ₹29.81 | 285.64 | |
Jun2022 | ₹7.73 | -54.21 | |
Mar2022 | ₹16.88 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD